Management Or Ownership Change
Expected: Q3 2026HIGH confidence
What: Stake size: 70.68%
Impact: ₹1,446 crore deal value
Novartis India Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +13.1%WeakRe-Entry
In , Novartis India Ltd (Pharma - MNC bulk Drugs) is outperforming Nifty 500 with +13.1% relative strength. Fundamentals: Weak.
Novartis India Ltd Key Facts
- PE Ratio
- 28.2x
- Market Cap
- ₹2,747 Cr
- PAT Growth YoY
- -36%
- Revenue Growth YoY
- -8%
- OPM
- 26.0%
- RS vs Nifty 500
- +13.1%
PE: Mid ContractionStrong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
💪Debt reduced 20% YoY — balance sheet strengthening
💰Trading 45% above estimated fair value — significant premium
Earnings Acceleration Triggers
1. Management Or Ownership Change
Q3 2026HIGH
2. New Product Or Brand Launch
2026-2027MEDIUM
3. Revenue Growth Target guidance raised
HIGH
Key Risks
1. Income tax demand of ₹10
MEDIUM2. Ongoing patent disputes for key drugs like ribociclib and Entresto generic compe
MEDIUMSector-Specific Signals
Operating Margin26.03%-5.44%
Debtors Turnover Ratio7.28xNot Given
Return on Capital Employed60.87%Not Given
Employee Count56Not Given
Key Numbers
PAT Growth YoY
-36%
Inflection Down
Revenue YoY
-7%
Inflection Down
Operating Margin
26.0%
-200 bps YoY
PE Ratio
28.2
Current Price
₹1,112
Dividend Yield
2.25%
Fundamental Score
29/100
Weak
3Y PAT CAGR
+19%
Market Cap
2.7K Cr
Valuation
Significantly Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
Why Are Novartis India Ltd's Earnings Accelerating?
Based on Q3 FY26 (web) earnings • Updated Apr 18, 2026
New Product Or Brand Launch
Expected: 2026-2027MEDIUM confidence
What: Pipeline assets: Radioligand Therapy
Revenue Growth Target guidance raised
HIGH confidence
What: 5% → 6%
What Are the Key Risks for Novartis India Ltd?
Earnings deceleration risks from management commentary
Income tax demand of ₹10
MEDIUMTrigger: Income tax demand of ₹10.28 crore for AY 2020-21 and DVAT dispute of ₹10.89 crore.
Impact: PAT impact: ₹21.17 Cr combined demand
Management view: Filing appeals and seeking stays in Delhi High Court
Monitor: regulatory
Ongoing patent disputes for key drugs like ribociclib and Entresto generic compe
MEDIUMTrigger: Ongoing patent disputes for key drugs like ribociclib and Entresto generic competition.
Management view: Challenging patent office delays in court
Monitor: litigation
What Did Novartis India Ltd Report This Quarter?
Headline numbers from the latest earnings call
Revenue
₹85.90 Cr
YoY -7.63%QoQ -4.9%
Revenue faced headwinds due to pricing pressures and consistent generic competition in core categories.
EBITDA
₹22.36 Cr
YoY -12.59%Margin 26.03%
Margins hit the lowest level in recent quarters due to mounting cost pressures and a decline in high-value product sales.
PAT
₹16.09 Cr
YoY -36.78%QoQ -33.57%
Profitability was severely impacted by operational challenges and a sharp reversal in sales momentum.
Other Highlights
• Debtors turnover ratio for H1 FY26 fell to 7.28 times, indicating deteriorating working capital management.
• Stock underperformed dramatically with a negative alpha of 20.72 percentage points against the Sensex.
• Company remains debt-free despite the sharp decline in quarterly profitability.
What Sector Metrics Matter for Novartis India Ltd?
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
Operating Margin
26.03%
YoY -5.44%QoQ -5.08%
Why: Compression due to mounting cost pressures and pricing challenges in the core pharmaceutical business.
Debtors Turnover Ratio
7.28x
YoY Not GivenQoQ Not Given
Why: Deteriorating working capital management and longer collection periods for receivables.
Return on Capital Employed
60.87%
YoY Not GivenQoQ Not Given
Why: Efficient capital deployment in operations despite shareholder return dilution.
Employee Count
56
YoY Not GivenQoQ Not Given
Why: Reflects the lean structure of the listed entity following years of strategic realignments.
What Is Novartis India Ltd's Management Guidance?
Forward-looking targets from management for FY26
Revenue Outlook
low single-digit %
Margin Outlook
Expect margin drag from recent acquisitions and generic erosion
Management Tone: CAUTIOUS
Guidance Changes
RAISED
Revenue Growth Target: 5% → 6%
Inclusion of Avidity Biosciences acquisition and portfolio growth
How Fast Is Novartis India Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | -7% | -4% | Inflection Down |
| PAT (Net Profit) | -36% | +19% | Inflection Down |
| OPM | 26.0% | -200 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 18, 2026.
Other Top Pharma - MNC bulk Drugs Stocks Beating Nifty 500
Frequently Asked Questions: Novartis India Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Novartis India Ltd's latest quarterly results?
Novartis India Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: -36.0% (inflecting downward)
- Revenue Growth YoY: -7.5%
- Operating Margin: 26.0% (volatile)
Is Novartis India Ltd's profit growing or declining?
Novartis India Ltd's profit is declining with an inflecting downward trend.
- PAT Growth YoY: -36.0% (latest quarter)
- PAT Growth QoQ: -33.3% (sequential)
- 3-Year PAT CAGR: +18.8%
- Trend: Inflecting downward — consistent growth pattern
What is Novartis India Ltd's revenue growth trend?
Novartis India Ltd's revenue growth trend is inflecting downward.
- Revenue Growth YoY: -7.5%
- Revenue Growth QoQ: -4.4% (sequential)
- 3-Year Revenue CAGR: -3.8%
How is Novartis India Ltd's operating margin trending?
Novartis India Ltd's operating margin is volatile.
- Current OPM: 26.0%
- OPM Change YoY: -2.0% basis points
- OPM Change QoQ: 0.0% basis points
What is Novartis India Ltd's 3-year profit and revenue CAGR?
Novartis India Ltd's long-term compounding rates
- 3-Year Profit CAGR: +18.8%
- 3-Year Revenue CAGR: -3.8%
Is Novartis India Ltd's growth accelerating or decelerating?
Novartis India Ltd's earnings growth is inflecting downward with negative momentum on a sequential basis.
- YoY Acceleration: -56.0% bps
- Sequential Acceleration: -19.0% bps
What is Novartis India Ltd's trailing twelve month (TTM) performance?
Novartis India Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹97 Cr
- TTM PAT Growth: +12.8% YoY
- TTM Revenue: ₹348 Cr
- TTM Revenue Growth: -1.4% YoY
- TTM Operating Margin: 28.0%
Is Novartis India Ltd overvalued or undervalued?
Novartis India Ltd appears significantly overvalued based on our fair value analysis.
- Valuation Signal: Significantly Overvalued
- Current PE: 28.2x
- Price-to-Book: 3.5x
What is Novartis India Ltd's current PE ratio?
Novartis India Ltd's current PE ratio is 28.2x.
- Current PE: 28.2x
- Market Cap: 2.7K Cr
- Dividend Yield: 2.25%
How does Novartis India Ltd's valuation compare to its history?
Novartis India Ltd's current PE is 28.2x.
- Current PE: 28.2x
- Valuation Assessment: Significantly Overvalued
What is Novartis India Ltd's price-to-book ratio?
Novartis India Ltd's price-to-book ratio is 3.5x.
- Price-to-Book (P/B): 3.5x
- Book Value per Share: ₹314
- Current Price: ₹1112
Is Novartis India Ltd a fundamentally strong company?
Novartis India Ltd is rated Weak with a fundamental score of 29/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: -7.5% (10% weight)
- PAT Growth YoY: -36.0% (10% weight)
- PAT Growth QoQ: -33.3% (10% weight)
- Margins stable (10% weight)
Is Novartis India Ltd debt free?
Novartis India Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹4 Cr
What is Novartis India Ltd's return on equity (ROE) and ROCE?
Novartis India Ltd's return ratios over recent years
- FY2023: ROCE 15.0%
- FY2024: ROCE 16.0%
- FY2025: ROCE 17.0%
Is Novartis India Ltd's cash flow positive?
Novartis India Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹75 Cr
- Free Cash Flow (FCF): ₹72 Cr
- CFO/PAT Ratio: 74% (adequate)
What is Novartis India Ltd's dividend yield?
Novartis India Ltd's current dividend yield is 2.25%.
- Dividend Yield: 2.25%
- Current Price: ₹1112
Who holds Novartis India Ltd shares — promoters, FII, DII?
Novartis India Ltd's shareholding pattern (Mar 2026)
- Promoters: 70.7%
- FII (Foreign): 0.2%
- DII (Domestic): 0.5%
- Public: 28.6%
Is promoter holding increasing or decreasing in Novartis India Ltd?
Novartis India Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 70.7% (Mar 2026)
- Previous Quarter: 70.7% (Dec 2025)
- Change: 0.00% (stable)
How long has Novartis India Ltd been outperforming Nifty 500?
Novartis India Ltd has been outperforming Nifty 500 for 2 consecutive weeks, indicating early-stage outperformance.
Is Novartis India Ltd a new momentum entry or an established outperformer?
Novartis India Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
What are the growth catalysts for Novartis India Ltd?
Novartis India Ltd has 3 key growth catalysts identified from recent earnings analysis
- Management Or Ownership Change — Total exit of the parent company from the listed entity will lead to a complete shift in corporate strategy and governance.
- New Product Or Brand Launch — New high-value therapies could offset the decline in older off-patent drug sales.
- Revenue Growth Target guidance raised — Inclusion of Avidity Biosciences acquisition and portfolio growth
What are the key risks in Novartis India Ltd?
Novartis India Ltd has 2 key risks worth monitoring
- [MEDIUM] Income tax demand of ₹10 — Income tax demand of ₹10.28 crore for AY 2020-21 and DVAT dispute of ₹10.89 crore.
- [MEDIUM] Ongoing patent disputes for key drugs like ribociclib and Entresto generic compe — Ongoing patent disputes for key drugs like ribociclib and Entresto generic competition.
What is Novartis India Ltd's management guidance for growth?
Novartis India Ltd's management has provided the following forward guidance for FY26
- Revenue outlook: low single-digit %
- Margin outlook: Expect margin drag from recent acquisitions and generic erosion
- Capex plan: Not Given for US manufacturing sites and R&D expansion
- Management tone: cautious
- Milestone: [RAISED] Revenue Growth Target: 5% → 6%
What sector-specific metrics matter most for Novartis India Ltd?
Novartis India Ltd's most important sub-sector-specific KPIs from the latest concall
- Operating Margin: 26.03% (YoY -5.44%) (QoQ -5.08%) — Compression due to mounting cost pressures and pricing challenges in the core pharmaceutical business.
- Debtors Turnover Ratio: 7.28x (YoY Not Given) (QoQ Not Given) — Deteriorating working capital management and longer collection periods for receivables.
- Return on Capital Employed: 60.87% (YoY Not Given) (QoQ Not Given) — Efficient capital deployment in operations despite shareholder return dilution.
- Employee Count: 56 (YoY Not Given) (QoQ Not Given) — Reflects the lean structure of the listed entity following years of strategic realignments.
Is Novartis India Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Novartis India Ltd may be worth studying
- Cash flow is positive — CFO ₹75 Cr
What is the investment thesis for Novartis India Ltd?
Novartis India Ltd investment thesis summary:
Research Signals (Bull Case)
- Growth catalyst: Management Or Ownership Change
Risk Factors (Bear Case)
- Appears significantly overvalued
- Key risk: Income tax demand of ₹10
What is the future outlook for Novartis India Ltd?
Novartis India Ltd's forward outlook based on current data signals
- Earnings Trend: inflecting downward
- Revenue Trend: inflecting downward
- Margin Trend: volatile
- Valuation: Significantly Overvalued
- Key Catalyst: Management Or Ownership Change
- Key Risk: Income tax demand of ₹10
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.